Feb 16 Alexion Pharmaceuticals Inc
reported an 18.5 percent rise in fourth-quarter revenue, helped
by demand for its costly rare blood disorder drug Soliris.
The biotechnology company, which announced the resignations
of its chief executive and chief financial officer in December,
said total revenue rose to $831 million from $701 million, a
The company's net income rose to $93 million, or 41 cents
per share, in the quarter ended Dec. 31, from $67 million, or 29
cents per share, a year earlier.
(Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb